AUTHORS
Rui Jiang, Zhibo Zhang2, Wenqiang Qu3, Meiyu Chen4, Qing Yuan Wang5, Linlin Wang6, Qian Wang7, Jia Yin, MD, PhD8, Suning Chen9, Depei Wu Sr, MD10, Zhao Zeng, PhD11
AFFILIATIONS
1 First Affiliated Hospital of Soochow University, Suzhou, China
2 First Affiliated Hospital of Soochow University, Suzhou, China
3 First Affiliated Hospital of Soochow University, Suzhou, China
4 Changzhou No.2 People's Hospital, Changzhou, China
5 First Affiliated Hospital of Soochow University, Suzhou, China
6 Yancheng No.1 People's Hospital, Yancheng, China
7 First Affiliated Hospital of Soochow University, Suzhou, China
8 First Affiliated Hospital of Soochow University, Suzhou, China
9 First Affiliated Hospital of Soochow University, Suzhou, China
10 First Affiliated Hospital of Soochow University, Suzhou, China
11 First Affiliated Hospital of Soochow University, Suzhou, China
ABSTRACT
Background: Systemic mastocytosis (SM), especially advanced SM (AdvSM), carries a poor prognosis despite available KIT inhibitors (eg. avapritinib, midostaurin). The role of leukemia inhibitory factor (LIF), a pleiotropic IL-6 family cytokine, remains undefined in SM. We investigated LIF dysregulation in SM, elucidated its mechanistic link to oncogenic KIT D816V, and evaluated the therapeutic efficacy of LIF/LIFR blockade as monotherapy and in combination with KIT inhibitors.
Methods: We queried public transcriptomic datasets (GSE103223, GSE216446, GSE222830) and performed RNA-sequencing on bone marrow (BM). Serum LIF was quantified by ELISA in an independent cohort (including healthy controls and SM). CRISPR-Cas9 generated LIF knockout (KO) in KIT D816V-transduced HMC-1.1 cells. Proliferation, colony formation, and apoptosis were assessed in vitro, alongside cell-derived xenograft (CDX) models in vivo. Mechanistic studies integrated RNA-seq, CUT&Tag, and immunoblotting. Pharmacologic LIF/LIFR inhibition employed EC359.
Results: LIF mRNA and protein were significantly elevated in SM patients versus controls and other myeloid neoplasms (p<0.01). KIT D816V ectopic expression drove LIF upregulation, while avapritinib and midostaurin suppressed LIF expression in KIT D816V-transduced HMC-1.1 and P815 cells. LIF KO profoundly impaired proliferation and colony formation across serial passages. In CDX models, LIF KO reduced tumor burden, decreased peripheral blood disease, and extended survival (p=0.0025). Mechanistically, integrative CUT&Tag and transcriptomic analyses identified EGR1 as a direct transcriptional activator of LIF downstream of KIT D816V. LIF KO abrogated JAK2/STAT3 signaling, and STAT3 inhibition recapitulated the anti-proliferative phenotype. CCL2 emerged as a critical downstream effector, markedly downregulated upon LIF KO (log2FC= -0.741, adj. p<0.001), and CCL2 overexpression rescued the proliferative defect, validating the KIT-D816V-EGR1-LIF-JAK2/STAT3-CCL2 axis. Pharmacologic LIF/LIFR blockade with EC359 inhibited HMC-1.1 growth (IC50=0.48 µM), induced apoptosis, and suppressed CDX tumor growth. Notably, EC359 synergized with avapritinib and midostaurin (Loewe synergy scores 12.08 and 5.36, respectively), yielding significantly enhanced apoptosis over single agents.
Conclusions: We identify LIF as a novel, KIT D816V-driven oncogenic cytokine in SM that promotes proliferation via the JAK2/STAT3-CCL2 cascade. Targeting LIF/LIFR with EC359 demonstrates potent preclinical efficacy and marked synergy with standard-of-care KIT inhibitors, providing a strong translational rationale for clinical trials in SM.
DISCLOSURES
Zhao Zeng, PhD: No relevant conflicts of interest to declare.